Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.

@article{Lawitz2017ShortdurationTW,
  title={Short-duration treatment with elbasvir/grazoprevir and sofosbuvir for hepatitis C: A randomized trial.},
  author={Eric J. Lawitz and Fred F Poordad and Julio Guti{\'e}rrez and Jennifer T Wells and Carmen E Landaverde and Barbara I. Evans and Anita Yee Mei Howe and Hsueh-Cheng Huang and Jerry Jing Li and Peggy May Hwang and Frank J. Dutko and Michael N. Robertson and Janice Wahl and Eliav Barr and Barbara A Haber},
  journal={Hepatology},
  year={2017},
  volume={65 2},
  pages={439-450}
}
Direct-acting antiviral agents (DAAs) represent the standard of care for patients with hepatitis C virus (HCV) infection. Combining DAAs with different mechanisms may allow for shorter treatment durations that are effective across multiple genotypes. The aim of the C-SWIFT study was to identify the minimum effective treatment duration across multiple genotypes. C-SWIFT was an open-label, single-center trial in treatment-naïve patients with chronic HCV genotype (GT)1 or 3 infection. All patients… CONTINUE READING